Oniangue-Ndza C, Strittmatter G, Lucas A, Wilson M, Kassahun S, Singh P. Pharmacoeconomic analysis of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer in Switzerland. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S95. doi: 10.1016/j.jval.2022.09.464
Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025